|
A phase II, open-label, multi-arm study of TAS-115 for castration-resistant prostate cancer patients with bone metastases. |
|
|
Consulting or Advisory Role - Janssen; Takeda |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Fujifilm; Janssen; Sanofi; Takeda |
Research Funding - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Chugai Pharma; Janssen; MSD; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda |
Consulting or Advisory Role - Bayer; Janssen; Merck; Ono Pharmaceutical; Sanofi |
Research Funding - Astellas Pharma; AstraZeneca; Janssen; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda |
|
|
Speakers' Bureau - Bayer; Daiichi Sankyo; Kyowa Hakko Kirin; Sanofi |
Research Funding - Astellas Pharma; Nihonkayaku; Taiho Pharmaceutical; Takeda |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Janssen; Kissei Pharmaceutical; Nihon Medi-Physics; Sanofi; Takeda |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Janssen; Nihonkayaku; Sanofi; Takeda |
Research Funding - Asahi Kasei; Astellas Pharma; Bayer; Chugai Pharma; Daiichi Sankyo; Kissei Pharmaceutical; Kyorin; Nihonkayaku; Nippon Shinyaku; Pfizer; Sanofi; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma; Takeda |
|
|
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Chugai Pharma; Janssen; Novartis; Ono Pharmaceutical; Pfizer; Sanofi |